1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow CD22 Positive: new trials by email Literature Review of CD22 Positive trials Research Report on CD22 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
Burkitt Lymphoma (1)
DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Tumor Virus Infections (1)
M.D. Anderson Cancer Center (1)
United States (1)
Nitin Jain (1)